5,456 Shares in Repligen Corporation $RGEN Acquired by Trevian Wealth Management LLC

Key Points

• Trevian Wealth Management LLC acquired 5,456 shares of Repligen Corporation, valued at approximately $679,000, making it the 22nd largest holding in their portfolio.
• Several institutional investors, including Price T Rowe Associates and New York State Common Retirement Fund, have increased their stakes in Repligen, which is owned by 97.64% of institutional investors.
• Wall Street analysts have mixed ratings for Repligen, with a consensus rating of "Moderate Buy" and an average target price of $169.62.

Trevian Wealth Management LLC purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,456 shares of the biotechnology company's stock, valued at approximately $679,000. Repligen comprises approximately 0.4% of Trevian Wealth Management LLC's portfolio, making the stock its 22nd biggest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Repligen by 1.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock valued at $130,317,000 after purchasing an additional 13,284 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock worth $124,727,000 after purchasing an additional 32,665 shares during the period. New York State Common Retirement Fund increased its position in shares of Repligen by 7.6% during the 1st quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock worth $79,574,000 after purchasing an additional 43,946 shares during the last quarter. Finally, Stephens Investment Management Group LLC raised its holdings in Repligen by 0.5% in the 1st quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company's stock valued at $68,651,000 after buying an additional 2,741 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Barclays lifted their target price on shares of Repligen from $150.00 to $160.00 and gave the company an "overweight" rating in a report on Thursday, October 2nd. Jefferies Financial Group decreased their price target on Repligen from $145.00 to $135.00 and set a "hold" rating on the stock in a research note on Friday, September 12th. Finally, Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $169.62.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Stock Down 1.3%

Shares of Repligen stock opened at $148.81 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a market capitalization of $8.37 billion, a P/E ratio of -595.22, a P/E/G ratio of 2.78 and a beta of 1.08. The company has a 50 day moving average of $124.60 and a 200 day moving average of $125.70.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company's revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.